Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort

• Published in: Atherosclerosis Vol. 263; pp. 398 - 404
• Main Authors: Maggi, Paolo, Bellacosa, Chiara, Leone, Armando, Volpe, Anna, Ricci, Elena Delfina, Ladisa, Nicoletta, Cicalini, Stefania, Grilli, Elisabetta, Viglietti, Rosaria, Chirianni, Antonio, Bellazzi, Lara Ines, Maserati, Renato, Martinelli, Canio, Corsi, Paola, Celesia, Benedetto Maurizio, Sozio, Federica, Angarano, Gioacchino
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.08.2017
• Subjects: Adult; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Atazanavir; Atazanavir Sulfate - therapeutic use; Atherosclerosis; Benzoxazines - therapeutic use; Biomarkers - blood; Brachial Artery - physiopathology; Cardiovascular; Cardiovascular Diseases - diagnostic imaging; Cardiovascular Diseases - etiology; Cardiovascular Diseases - physiopathology; Cardiovascular risk; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Darunavir; Darunavir - therapeutic use; Efavirenz; Endothelium, Vascular - physiopathology; Female; HIV; HIV Infections - complications; HIV Infections - diagnosis; HIV Infections - drug therapy; HIV Infections - virology; Humans; Inflammation Mediators - blood; Italy; Lipids - blood; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir - therapeutic use; Time Factors; Treatment Outcome; Vasodilation; Atazanavir; HIV; Darunavir; Efavirenz; Cardiovascular risk; Atherosclerosis

Abstract Background and aims PREVALEAT (PREmature VAscular LEsions and Antiretroviral Therapy) II is a multicenter, longitudinal cohort study aimed at the evaluation of cardiovascular risk among advanced HIV-positive, treatment-naïve patients starting their first therapy. We hypothesized that these...